SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First...